Oncology Central

International CAR-T therapy trial yields high rates of durable remission for NHL

Results from a pair of clinical trials evaluating the CAR-T therapy Kymriah™ (also known as CTL019) have demonstrated long-lasting remissions in non-Hodgkin’s lymphoma patients. The findings were presented recently at the 59th American Society of Hematology Annual Meeting and Exposition (December 9–12, 2017, GA, USA) and published in the New England Journal of Medicine.

In this global, multi-center trial, termed JULIET, 38%of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who received the investigational treatment had a partial or complete response at 3 months. Approximately 73% of patients who responded remained cancer-free at 6 months.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.